Johnson & Johnson
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1886-01-01
- Employees
- 131.9K
- Market Cap
- $392.2B
- Website
- http://www.jnj.com
- Introduction
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.
New Guselkumab Data Indicate Robust Effectiveness in Crohn Disease, Plaque Psoriasis
Guselkumab (Tremfya) demonstrated effectiveness in clearing overlooked plaque psoriasis in SPECTREM trial, achieving optimal IGA scores in 74.2% of patients vs. 12.4% with placebo. In GRAVITI study, guselkumab showed rapid onset of action in Crohn disease, with 56.1% achieving clinical remission vs. 21.4% with placebo. Guselkumab is the first fully human, dual-acting monoclonal antibody approved for ulcerative colitis.
European Medicines Agency Confirms Acceptance of Marketing Authorization
EMA accepts Alvotech's MAA for AVT05, a biosimilar to Simponi®, expected to complete approvals by Q4 2025.
7 Alzheimer's and Parkinson's Programs Discarded in 2024
Despite approvals for Leqembi and Kisunla, attrition in Alzheimer’s and Parkinson’s pipelines persists, with Roche, Johnson & Johnson, Sage Therapeutics, and Otsuka discontinuing programs. Analysts attribute these decisions to clinical trial data and evolving commercial opportunities, noting the Alzheimer’s market is projected to be worth $15.5 billion by 2031, while Parkinson’s drugs are expected to reach $6.63 billion by 2029.
Big Pharma Doubles Down on China
Eli Lilly invests $212 million to expand its Suzhou plant, following China's approval of its weight loss drug Zepbound. Other pharmaceutical giants like Bayer and Roche also expand in China, highlighting the sector's resilience amid economic challenges. China's healthcare sector reforms and large market attract foreign investment, despite pricing pressures and competition from local firms. Multinationals increasingly partner with Chinese biotech companies for innovation and market access.
Balancing Benefits and Risks of Amivantamab
Amivantamab's notable adverse effects include infusion-related reactions, skin toxicities like dermatitis paronychia, and increased risk of venous thromboembolism. Management strategies involve dose splitting, premedication, prophylactic antibiotics, and anticoagulation. Despite higher toxicity compared to osimertinib, amivantamab-lazertinib combinations offer more durable responses and longer progression-free survival.
Indirect Comparison Shows Superiority of Cilta-Cel vs SOC Regimens in Lenalidomide Refractory Multiple Myeloma
Ciltacabtagene autoleucel (cilta-cel; Carvykti) demonstrated superior outcomes compared to standard-of-care (SOC) regimens in relapsed/refractory multiple myeloma refractory to lenalidomide, with higher overall response rates, very good partial responses, and complete responses. The analysis, presented at the 21st Annual International Myeloma Society Annual Meeting, included 208 cilta-cel patients from the phase 3 CARTITUDE-4 trial and 800 patients from nine other trials. Cilta-cel also showed benefits in progression-free survival and time to next treatment, confirming its superiority over various SOC regimens.
2024 PharmaVoice 100s: Cancer Care Visionaries
Cancer has become more manageable due to tailored treatments, with leaders in oncology pushing for genetic insights and data research. This year's Cancer Care Visionaries include Dr. Hesham Abdullah, Jason Bock, Arnon Chait, Raffaele Colombo, Dr. Yusri Elsayed, Mark Erlander, Dr. Marjorie Green, Raquel Izumi, Dr. Biljana Naumovic, Dr. Amita Patnaik, Dr. Mary Pinder-Schenck, Amoolya Singh, and AmirAli Talasaz, each contributing unique perspectives on cancer therapy and leadership.
Stelara May be Effective for Type 1 Diabetes in Adolescents
Stelara (ustekinumab) showed potential in preserving insulin production by reducing Th17.1 cells in a UK phase 2 study, suggesting it could prevent or reduce the need for insulin in type 1 diabetes patients if started early.
Big Pharma earnings hang hope on the next generation of blockbusters
Big Pharma companies like Pfizer, Johnson & Johnson, Biogen, and Novartis are focusing on new products to drive future growth amid patent cliffs and market challenges. Pfizer's Prevnar 20 holds strong market share despite competition, while J&J's Tremfya gains traction as Stelara faces biosimilar competition. Biogen's Leqembi struggles with uptake due to infrastructure challenges, and Novartis relies on new oncology drugs to offset patent expirations and price negotiations.
How medtech often gets more innovation bang for its R&D buck
Pharma companies like Merck and Moderna spend significantly more on R&D than medtech firms, but higher spending doesn’t always correlate with more innovation output. Medtronic, with 8.45% R&D intensity, generated 443 patents and 305 publications in 2023, while Moderna, spending 70.75% of revenue on R&D, produced only 27 patents and 245 publications. Medtech firms consistently show higher patent output per R&D dollar invested.
© Copyright 2025. All Rights Reserved by MedPath